AKEBIA THERAPEUTICS, INC.: prepaid expenses and other current assets
Prepaid expenses and other current assets for AKEBIA THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All AKEBIA THERAPEUTICS, INC. financial histories
What this measure means
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
Exact concept: us-gaap:PrepaidExpenseAndOtherAssetsCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 5,470,000 | USD | 2026-02-26 | 10-K · 0001517022-26-000020 |
| At date | 2024-12-31 | 11,350,000 | USD | 2026-02-26 | 10-K · 0001517022-26-000020 |
| At date | 2023-12-31 | 20,243,000 | USD | 2025-03-13 | 10-K · 0001628280-25-012470 |
| At date | 2022-12-31 | 32,864,000 | USD | 2024-03-14 | 10-K · 0001628280-24-011270 |
| At date | 2022-09-30 | 28,940,000 | USD | 2023-08-28 | 10-K/A · 0001628280-23-030697 |
| At date | 2021-12-31 | 33,140,000 | USD | 2023-08-28 | 10-K/A · 0001628280-23-030697 |
| At date | 2020-12-31 | 14,877,000 | USD | 2022-03-01 | 10-K · 0001628280-22-004522 |
| At date | 2019-12-31 | 6,626,000 | USD | 2021-02-25 | 10-K · 0001628280-21-003283 |
| At date | 2018-12-31 | 15,724,000 | USD | 2020-03-12 | 10-K · 0001564590-20-010491 |
| At date | 2017-12-31 | 6,348,000 | USD | 2019-03-26 | 10-K · 0001564590-19-009340 |
| At date | 2016-12-31 | 2,155,000 | USD | 2018-03-12 | 10-K · 0001564590-18-005286 |
| At date | 2015-12-31 | 2,563,000 | USD | 2017-03-06 | 10-K · 0001564590-17-003466 |
| At date | 2014-12-31 | 1,562,000 | USD | 2016-03-14 | 10-K · 0001564590-16-014700 |
| At date | 2013-12-31 | 740,000 | USD | 2015-03-04 | 10-K · 0001564590-15-001260 |
Related financial histories
- AKEBIA THERAPEUTICS, INC.: total assets
- AKEBIA THERAPEUTICS, INC.: total liabilities
- AKEBIA THERAPEUTICS, INC.: stockholders equity
- AKEBIA THERAPEUTICS, INC.: cash and cash equivalents
- AKEBIA THERAPEUTICS, INC.: net income or loss
- AKEBIA THERAPEUTICS, INC.: operating cash flow
- AKEBIA THERAPEUTICS, INC.: capital expenditure payments
- AKEBIA THERAPEUTICS, INC.: contract revenue excluding tax
- AKEBIA THERAPEUTICS, INC.: financing cash flow
- AKEBIA THERAPEUTICS, INC.: investing cash flow
- AKEBIA THERAPEUTICS, INC.: retained earnings or deficit
- AKEBIA THERAPEUTICS, INC.: basic weighted-average shares
- AKEBIA THERAPEUTICS, INC.: diluted weighted-average shares
- AKEBIA THERAPEUTICS, INC.: basic earnings per share
- AKEBIA THERAPEUTICS, INC.: diluted earnings per share
- AKEBIA THERAPEUTICS, INC.: income tax expense or benefit
- AKEBIA THERAPEUTICS, INC.: net property, plant and equipment
- AKEBIA THERAPEUTICS, INC.: share-based compensation expense
- AKEBIA THERAPEUTICS, INC.: operating income or loss
- AKEBIA THERAPEUTICS, INC.: current assets
- AKEBIA THERAPEUTICS, INC.: current liabilities
- AKEBIA THERAPEUTICS, INC.: current accounts payable
- AKEBIA THERAPEUTICS, INC.: goodwill carrying amount
- AKEBIA THERAPEUTICS, INC.: net finite-lived intangible assets
- AKEBIA THERAPEUTICS, INC.: net current accounts receivable
- AKEBIA THERAPEUTICS, INC.: operating expenses
- AKEBIA THERAPEUTICS, INC.: net inventory
- AKEBIA THERAPEUTICS, INC.: cost of revenue
- AKEBIA THERAPEUTICS, INC.: selling, general and administrative expense
- AKEBIA THERAPEUTICS, INC.: research and development expense
- AKEBIA THERAPEUTICS, INC.: common shares outstanding
- AKEBIA THERAPEUTICS, INC.: cash including restricted cash
- AKEBIA THERAPEUTICS, INC.: accumulated other comprehensive income or loss
- AKEBIA THERAPEUTICS, INC.: operating lease right-of-use asset
- AKEBIA THERAPEUTICS, INC.: operating lease liability
- AKEBIA THERAPEUTICS, INC.: long-term debt
- AKEBIA THERAPEUTICS, INC.: gross property, plant and equipment
- AKEBIA THERAPEUTICS, INC.: accumulated depreciation on property, plant and equipment
- AKEBIA THERAPEUTICS, INC.: net intangible assets excluding goodwill
- AKEBIA THERAPEUTICS, INC.: other noncurrent assets
- AKEBIA THERAPEUTICS, INC.: other noncurrent liabilities
- AKEBIA THERAPEUTICS, INC.: accrued current liabilities
- AKEBIA THERAPEUTICS, INC.: current contract liabilities
- AKEBIA THERAPEUTICS, INC.: net deferred tax assets
- AKEBIA THERAPEUTICS, INC.: pre-tax income or loss from continuing operations
- AKEBIA THERAPEUTICS, INC.: profit or loss including noncontrolling interests
- AKEBIA THERAPEUTICS, INC.: comprehensive income or loss
- AKEBIA THERAPEUTICS, INC.: net income available to common stockholders
- AKEBIA THERAPEUTICS, INC.: general and administrative expense
- AKEBIA THERAPEUTICS, INC.: depreciation expense
- AKEBIA THERAPEUTICS, INC.: depreciation, depletion and amortization
- AKEBIA THERAPEUTICS, INC.: amortization of intangible assets
- AKEBIA THERAPEUTICS, INC.: other nonoperating income or expense
- AKEBIA THERAPEUTICS, INC.: current income tax expense or benefit
- AKEBIA THERAPEUTICS, INC.: deferred income tax expense or benefit
- AKEBIA THERAPEUTICS, INC.: interest paid, net
- AKEBIA THERAPEUTICS, INC.: proceeds from issuing common stock
- AKEBIA THERAPEUTICS, INC.: operating lease payments
- AKEBIA THERAPEUTICS, INC.: change in accounts receivable
- AKEBIA THERAPEUTICS, INC.: change in inventories
- AKEBIA THERAPEUTICS, INC.: change in accounts payable
Inspect the source
- Entity
- AKEBIA THERAPEUTICS, INC. / CIK 0001517022
- Captured
- 2026-09-20T09:13:55.431Z
- SEC response SHA-256
eca901731ec587f0de4c46106d46ca08fada346fffe215cee1b095d9bfe74258
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001517022.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))